Drug intelligence / Profile preview

Placebo to mepolizumab (AstraZeneca, EGPA)

Development stage: Unknown
Lead developer: GSK
Administration: Subcutaneous

Overview

Placebo to mepolizumab (AstraZeneca, EGPA) is the matching control substance used in the MANDARA Phase 3 clinical trial (NCT04157348). This trial was designed to compare the efficacy and safety of benralizumab against mepolizumab in patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) who are receiving standard of care therapy. The placebo consists of a 0.9% sodium chloride solution administered via subcutaneous injection, specifically formulated to match the administration volume and frequency of the active mepolizumab treatment (300 mg dose delivered as three 100 mg injections).

Other names: Placebo to Mepolizumab0.9% sodium chloride

Beyond the preview

Go deeper on Placebo to mepolizumab (AstraZeneca, EGPA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Placebo to mepolizumab (AstraZeneca, EGPA).

Explore the full profile